Federal rescheduling turned California cannabis license designations into real strategy decisions, not just paperwork. This post explains when and how to convert or split A/M licenses, why medical vs adult-use separation now matters for 280E and DEA planning, and why every link in the supply chain needs its own clearly defined medical channel.
Cannabis law has never been more contradictory. In the U.S., federal and state governments often regulate identical products under completely different legal frameworks. Hemp and marijuana can produce the same intoxicating effects, yet lawmakers treat them as fundamentally different. Medical marijuana now occupies a unique place under federal law while adult use marijuana remains prohibited.
Federal rescheduling has finally arrived, but it didn’t magically solve everything for California cannabis businesses. Instead, it created a new set of decisions: whether to pursue DEA registration as a medical operator, how and when to restructure DCC licenses, and what 280E relief actually looks like for mixed medical/adult use companies. This article walks through the concrete steps California operators should take now — including what to do if you missed the initial DEA registration window.
While most attention has focused on the recently concluded marijuana rescheduling hearing, an equally significant legal battle has unfolded in the D.C. Circuit over the final rescheduling order (“Final Order”). Petitioners, the Department of Justice, newly intervening parties, and amici participants have exchanged a series of briefs over the past month. Those filings may ultimately
When I first met Martin Jelsma (retiring as Programme Director Drugs & Democracy at the Transnational Institute) in 2019, I was a law clerk who, from day one, began following developments in international cannabis policy. At the time, I was trying to understand the intricate architecture of the international drug control treaties—how they functioned, how
Tomorrow morning at 10:00 a.m. PT, Harris Sliwoski attorney Jason Adelstone will join fellow cannabis industry professionals for a live webinar, The Cannabis Brief LIVE: Cannabis Rescheduling After the Hearing. The discussion will examine where federal cannabis rescheduling stands following the DEA administrative hearing process, what recent developments mean for the industry, and what cannabis
Harris Sliwoski is pleased to announce that Jared Schwass has joined the firm as an attorney in our California office. Jared advises entrepreneurs, investors, startups, and established companies operating in highly regulated industries, with a particular focus on the cannabis sector. His practice includes corporate transactions, mergers and acquisitions, regulatory compliance, licensing, land use, and
The hearing on the Notice of Proposed Rulemaking for the rescheduling of “marijuana” commenced on June 29, 2026 and will end tomorrow, July 15th. The Government brought two witnesses to the stand on the first day, and then seven prohibitionist organizations had the floor for the remaining seven days of the hearing. As I discussed
The DEA’s marijuana rescheduling hearing continues to raise important questions for cannabis businesses, investors, and the industry as a whole. If you’re trying to keep up with where things stand and what may come next, this upcoming MJBizDaily webinar is worth your time. Harris Sliwoski attorney Jason Adelstone will join a panel of industry professionals
Until last week, federal law prohibited marijuana users from owning or possessing firearms, even in states where marijuana is legal. In recent years, we have covered the differing opinions by federal courts challenging this status quo. On June 18, 2026, the Supreme Court held in a 9-0 decision in U.S. v. Hemani that 18 U.S.C.
